论文部分内容阅读
1992年5月～1994年12月体外放疗50～60Gy／5～6周加高剂量率（HDR）腔内放疗10～15Gy／4～6；k／5～9天，2.5Gy／次，Bid治疗食管鳞癌56例（综合组），与同期单纯体外放疗60～70Gy／6．5～7周52例（对照组）比较。综合组1、2年生存率和2年局控率分别为76．8％、51．8％和63．5％。明显高于对照组的42．3％、28．8％和32．6％。食管X线片示病变长度≤7cm和无食管轴向异常者，综合组3年生存率分别42．3％和40．9％，明显高于对照组的14．8％和14．3％。综合组食管瘘发生率为3．6％，晚期食管良性狭窄率为7．4％。
From May 1992 to December 1994, 50 to 60 Gy/5 to 6 weeks plus high dose rate (HDR) intracavitary radiotherapy 10 to 15 Gy/4 to 6; k/5 to 9 days, 2.5 Gy/time, Bid Treatment of esophageal squamous cell carcinoma in 56 cases (comprehensive group), compared with the same period in vitro 60 ~ 70Gy/6.5 to 7 weeks (control group). The overall 1-, 2-year survival rate and 2-year control rate were 76.8%, 51.8% and 63.5%, respectively. Significantly higher than the control group 42.3%, 28.8% and 32.6%. Esophageal X-ray films showed lesion length ≤ 7cm and no axial abnormalities in the esophagus. The 3-year survival rate of the comprehensive group was 42.3% and 40.9%, respectively, which was significantly higher than the 14.8% and 14.3% of the control group. The incidence of esophageal fistula was 3.6% in the comprehensive group and 7.4% in the advanced esophageal stricture.